Faecalibacterium prausnitzii: A butyrate producer in microbiome testing

A closer look at an important butyrate producer

Faecalibacterium prausnitzii is one of the frequently studied bacteria in the human colon. A stool test looks for its DNA and usually reports its proportion of the community detected. Laboratories may use metagenomic sequencing, 16S rRNA methods, or targeted quantitative PCR. How precisely the organism is identified, and how the result is reported, depend on the method.

The organism is sensitive to oxygen and difficult to grow under ordinary conditions. Microbiome analyses therefore often rely on molecular methods. Detecting DNA and establishing viability are different measurements: a test can also detect DNA from cells that are no longer alive.

Its ability to produce butyrate is particularly interesting. This short-chain fatty acid supplies energy to cells lining the colon and participates in barrier and immune signaling. Research on F. prausnitzii often describes lower abundance in active inflammatory bowel disease. That is an association, not proof that a low result causes the disease or that raising the abundance alone would be an effective treatment.

What one organism can reveal about the gut

If you have changing bowel habits, cramps, or bloating, it is understandable to wonder whether gut microbes contribute. F. prausnitzii’s role in fermentation provides a biological starting point. Its measured abundance, however, does not directly show how well the cells lining the gut are nourished or how intact their connections are.

Antibiotics, certain other medications, infections, and severely restricted fiber intake can accompany changes in the community. Medication history should also include frequent use of nonsteroidal anti-inflammatory drugs. These connections belong in the medical history; they do not justify stopping prescribed medication yourself because of a microbiome result.

A wider range of fermentable substrates can influence the community. Whether F. prausnitzii increases in response depends on the surrounding microbial environment. A change in its percentage therefore cannot be directly translated into an effect on inflammation, energy, or mood. Even repeat measurements need a clear question and cannot replace clinical measures of progress.

Reading the result in context

Reports often show the proportion of sequencing signals, although some provide a targeted quantitative measurement. Reference ranges differ between laboratories. Diet, age, and geographic background influence comparison populations; there is no universal cutoff for everyone.

A substantial abundance of F. prausnitzii alongside other fermenters, such as Roseburia, may be consistent with a capacity to produce butyrate. That does not mean large amounts are being produced at that moment. Activity, available substrates, and the metabolism of the rest of the community also matter.

Low results can occur with inflammatory conditions or changes in the community, but they can have other explanations too. They do not diagnose Crohn’s disease, ulcerative colitis, an impaired gut barrier, or a general “butyrate deficiency.” Other bacteria also contribute to butyrate production. A result below the detection limit may also reflect the method’s limitations.

Whether a dietary change makes sense should therefore not depend solely on the report. Symptoms, tolerance, and, where appropriate, established clinical measurements are more relevant. Someone who tolerates fiber poorly will not necessarily benefit from abruptly starting a high dose of a fermentable supplement.

What can change the measurement independently of health?

Collection, preservation, shipping, and analysis can affect the reported profile. The living organism’s oxygen sensitivity is particularly relevant to culture methods; DNA-based methods have their own stability and extraction limitations. Following the laboratory’s specific instructions is therefore more useful than making general assumptions about the sample’s “survival.”

Biological variation from day to day adds another layer. Different platforms may use different species boundaries and reference data. Even a real change between measurements does not prove that the most recently introduced intervention caused it.

What other information matters?

A record of symptoms, diet, and medications helps put the result in context. If intestinal inflammation is suspected, fecal calprotectin can answer a different, clinically established question. CRP is a nonspecific marker of systemic inflammation; metabolic tests may add information when there is an appropriate clinical reason. None of these investigations should be ordered simply to confirm a microbiome graphic.

Exercise load and sleep can also be relevant to everyday health. The important measure is whether an intervention improves symptoms, function, or a clinically meaningful outcome. A change in one laboratory value is not enough to establish that.

Frequently asked questions

What does a Faecalibacterium prausnitzii test measure?

It detects genetic material assigned to the species or to the group recognized by the method. A broader profile may also show other organisms and genetic functional potential. It does not automatically measure living cell counts, actual butyrate production, or inflammation.

How is the stool sample collected?

At home, collect the small amount specified in the kit’s instructions, label it correctly, and seal it securely. Clean hands and avoiding contact with the container’s inner surfaces help prevent contamination. Storage temperature and shipping time depend on the preservation system.

What does the result say about my health?

It describes an important part of the butyrate-producing community. Low abundance has been observed in several conditions, but it is not specific enough to diagnose an individual. A high result does not establish overall gut health either.

How reliable is the analysis?

Technical accuracy depends on the sample, database, and method. Clinical interpretation adds further uncertainty. A result can be reproducible without there being a validated target or a treatment matched to it. Comparisons need to account for differences in timing and methods.

How often should I be tested?

Annual testing, or testing every three to six months, is not a generally established preventive-care recommendation. Repeat tests should address a specific unanswered question and must not replace routine monitoring of an existing condition.

Can populations change quickly?

Yes. Medication, infections, and dietary changes can shift the community over a short period. There is no universal timetable for this species to reach a stable new baseline. The direction of a short-term change does not establish its long-term health value.

Is a low result diagnostic?

No. In particular, low abundance must not be equated with inflammatory bowel disease. When relevant symptoms are present, medical history and established investigations matter regardless of what the microbiome report shows.

What can I do after the test?

A variety of fiber sources that you tolerate can support your diet. With a sensitive gut, make changes gradually. Prebiotics, probiotics, and synbiotics need to be assessed for the particular product and use; the result does not identify a specific preparation to take. Sleep, movement, and avoiding unnecessary antibiotics are general health considerations, not a guaranteed F. prausnitzii treatment. Persistent symptoms, blood in the stool, or known intestinal disease warrant planning with a medical or nutrition professional.

Sources

• Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M (2017). Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. The ISME Journal, 11(4), 841-852. https://doi.org/10.1038/ismej.2016.176 PubMed

• Parsaei M, Sarafraz N, Moaddab SY, Ebrahimzadeh Leylabadlo H (2021). The importance of Faecalibacterium prausnitzii in human health and diseases. New Microbes and New Infections, 43, 100928. https://doi.org/10.1016/j.nmni.2021.100928 PubMed

• Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology, 10, 277. https://doi.org/10.3389/fimmu.2019.00277 PubMed

• Laudadio I, Fulci V, Palone F, Stronati L, Cucchiara S, Carissimi C (2018). Quantitative assessment of shotgun metagenomics and 16S rDNA amplicon sequencing in the study of human gut microbiome. OMICS, 22(4), 248-254. https://doi.org/10.1089/omi.2018.0013 PubMed

• Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O’Toole PW, Raes J, Hold G, Putignani L, Hvas CL, Nieuwdorp M, Sokol H, Ianiro G, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X PubMed